Drug Trial Radar · NCT07335198
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 5, 2026
Primary completion
Aug 13, 2026
Study completion Aug 13, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
Conditions
- Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin alfaDrug
Efimosfermin alfa to be administered
PlaceboDrug
Placebo to be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs), treatment related AEs and serious adverse events (SAEs)Time frame: Up to 90 days
- Number of participants with clinically significant changes in hematology, chemistry and urinalysis parametersTime frame: Up to 90 days
- Number of participants with clinically significant changes in 12 Lead electrocardiogram (ECG)Time frame: Up to 90 days
- Number of participants with clinically significant changes in vital signsTime frame: Up to 90 days
- Area under the serum drug concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC[0-t]) of efimosfermin alfaTime frame: Up to 90 days
- Area under the serum drug concentration versus time curve from time zero extrapolated to infinity (AUC[0-inf]) of efimosfermin alfaTime frame: Up to 90 days
- Maximum observed serum drug concentration, determined directly from the serum concentration-time data (Cmax) of efimosfermin alfaTime frame: Up to 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.